Logo image of AEON

AEON BIOPHARMA INC (AEON) Stock Fundamental Analysis

NYSEARCA:AEON - NYSE Arca - US00791X2099 - Common Stock - Currency: USD

0.405  +0.01 (+1.28%)

After market: 0.38 -0.03 (-6.17%)

Fundamental Rating

1

AEON gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. Both the profitability and financial health of AEON have multiple concerns. AEON does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AEON has reported negative net income.
AEON had a negative operating cash flow in the past year.
In multiple years AEON reported negative net income over the last 5 years.
AEON had a negative operating cash flow in each of the past 5 years.
AEON Yearly Net Income VS EBIT VS OCF VS FCFAEON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

1.2 Ratios

Industry RankSector Rank
ROA -116.07%
ROE N/A
ROIC N/A
ROA(3y)-176.64%
ROA(5y)-75.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AEON Yearly ROA, ROE, ROICAEON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 200 -200 -400

1.3 Margins

AEON does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AEON Yearly Profit, Operating, Gross MarginsAEON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 2K 4K

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for AEON has been increased compared to 1 year ago.
AEON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AEON Yearly Shares OutstandingAEON Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M
AEON Yearly Total Debt VS Total AssetsAEON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

AEON has an Altman-Z score of -87.56. This is a bad value and indicates that AEON is not financially healthy and even has some risk of bankruptcy.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -87.56
ROIC/WACCN/A
WACCN/A
AEON Yearly LT Debt VS Equity VS FCFAEON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

AEON has a Current Ratio of 0.48. This is a bad value and indicates that AEON is not financially healthy enough and could expect problems in meeting its short term obligations.
AEON has a Quick Ratio of 0.48. This is a bad value and indicates that AEON is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.48
Quick Ratio 0.48
AEON Yearly Current Assets VS Current LiabilitesAEON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

AEON shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -409.61%.
EPS 1Y (TTM)-409.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AEON is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.90% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y161.54%
EPS Next 2Y41.13%
EPS Next 3Y25.82%
EPS Next 5Y14.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AEON Yearly Revenue VS EstimatesAEON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2027 2028 2029 2030 100M 200M 300M 400M 500M
AEON Yearly EPS VS EstimatesAEON Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 20 -20 40 -40 -60 -80

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AEON. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 0.01, the valuation of AEON can be described as very cheap.
AEON is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.08, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 0.01
AEON Price Earnings VS Forward Price EarningsAEON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.45
AEON Per share dataAEON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40 50

4.3 Compensation for Growth

AEON's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AEON's earnings are expected to grow with 25.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.13%
EPS Next 3Y25.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AEON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AEON BIOPHARMA INC

NYSEARCA:AEON (4/17/2025, 8:04:02 PM)

After market: 0.38 -0.03 (-6.17%)

0.405

+0.01 (+1.28%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap15.05M
Analysts82.86
Price Target367.2 (90566.67%)
Short Float %N/A
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)119.35%
Min EPS beat(2)-74.02%
Max EPS beat(2)312.73%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7100%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)7100%
EPS NY rev (3m)7100%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.01
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 0.45
EPS(TTM)-0.56
EYN/A
EPS(NY)52.88
Fwd EY13056%
FCF(TTM)-1.29
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0
BVpS-4.12
TBVpS-4.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -116.07%
ROE N/A
ROCE -349.13%
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-176.64%
ROA(5y)-75.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.48
Quick Ratio 0.48
Altman-Z -87.56
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-409.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y161.54%
EPS Next 2Y41.13%
EPS Next 3Y25.82%
EPS Next 5Y14.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y750.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4773.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4773.24%
OCF growth 3YN/A
OCF growth 5YN/A